Biopharmaceutical company focused on neurological and endocrine-related diseases
3 AI-extracted insights from 2 sources — podcasts, YouTube channels, and X/Twitter accounts.
Based on 2 scored insights about Neurocrine Biosciences, Inc..
The 2 sources with the most insights about Neurocrine Biosciences, Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
The speaker praised a big quarter with 12% growth, strong sales of Ingrezza and Crenessity, and the acquisition of Vykat XR.
The speaker praised Ingrezza and said Crenessity was selling well, while offering no valuation or firm recommendation and noting uncertainty about a pipeline program.
The speaker praised a big quarter with 12% growth, strong sales of Ingrezza and Crenessity, and the acquisition of Vykat XR.
The speaker praised Ingrezza and said Crenessity was selling well, while offering no valuation or firm recommendation and noting uncertainty about a pipeline program.
Other assets that creators frequently mention in the same content as Neurocrine Biosciences, Inc..
The most active sources covering Neurocrine Biosciences, Inc. (NBIX) on Kazuha are @realmartinshkreli, @theshkrelipill. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 3 AI-extracted insights about Neurocrine Biosciences, Inc. (NBIX) from 2 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Neurocrine Biosciences, Inc. (NBIX) most frequently also discuss MU, NVDA, INTC, AMD, SNDK. See the "Discussed alongside" section above for full asset pages.